The PRECEYES Surgical System is compatible with a wide range of 23G, 25G and 27G instruments. The system can be used in patients under local or general anesthesia in a standard surgical setting.
The PRECEYES Surgical System has been successfully validated in clinical investigations and preclinical research. The PRECEYES Surgical System R1.1 has a CE mark and is commercially available for use.
Scaling and filtering of hand tremors yield unprecedented steadiness and precision. The robot is easily engaged to assist in specific tasks and movements are recorded for post-surgical evaluation and training puposes.
Preceyes B.V. is a medical robotics company with a CE-marked product for treatment of patients requiring vitreoretinal surgery. We fight visual impairment and blindness by developing novel, high-precision drug delivery treatments and by improving the treatment quality of existing vitreoretinal surgery. Our long-term vision is to transition eye surgery to its next evolution where robotics enables novel therapies, standardizes and improves surgical performance, and provides significant cost-saving by shifting the surgical suite to an office-based setting. Strong partnerships with excellent top-clinical institutes support our developments.
 |
 |
 |
Eindhoven, The Netherlands, June 5, 2020 – Preceyes B.V. has received the ISO-EN 13485:2016 certification for its quality management system, effectively obtaining approval for the continued commercialization and production of its CE-marked PRECEYES Surgical System Read more…
Eindhoven, The Netherlands, December 13, 2019 – Researchers from the Copenhagen University Hospital Rigshospitalet have concluded that robot-assisted vitreoretinal surgery improves precision and limits tissue damage compared with that of manual surgery. This comes initially Read more…
Eindhoven, The Netherlands, September 23, 2019 – Preceyes B.V., the medical robotics company developing and commercializing the first market-cleared robot for retina surgery, announced that it has appointed Dr. Kester Nahen as its Chief Commercial Read more…
